Molecular Response has introduced TargetX platform for the rapid discovery and validation of new oncology targets. The integrated platform, which features 144,000 living tumor specimens, genomic databases and patient derived tumor models, ...
Tags: TargetX platform, oncology targets
Life Technologies has introduced two bioinformatics offerings, which will allow cancer researchers new avenues of access to one of the largest genomics databases available, compiled by the former Compendia Bioscience. Oncomine Gene ...
Tags: Life Technologies, Oncomine Bioinformatics Solutions, Cancer Researchers
Moberg Derma has announced the discontinuation of the development of Limtop, an actinic keratosis drug, as it failed to reach the predefined efficacy target in a completed phase II trial. Moberg Derma president and CEO Peter Wolpert said ...
Tags: drug, Moberg Derma, actinic keratosis drug
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Nuvo Research's US licensing partner, Mallinckrodt, following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical ...
UK-based pharmaceutical development and device company Glide Pharma has appointed Dr. Mark Carnegie-Brown as its chief executive officer (CEO). Earlier to this appointment, Carnegie-Brown served as CEO of Evolutec, a biological drug ...
Tags: Glide Pharma, CEO, pharmaceutical
Kala Pharmaceuticals, a developer of products that effectively penetrate the mucosal barrier to treat various debilitating diseases, has received $11.5m in Series A equity financing round, led by new and existing investors. Kala said ...
Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs. Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor ...
Tags: drug discovery, biopharmaceutical, UCB
The UK biotechnology and personalized medicine company Epistem has received Good Clinical Laboratory Practice (GCLP) accreditation for its contract research division's histology and immunohistochemistry (IHC) laboratories. The contract ...
Tags: biotechnology, personalized medicine, Clinical Laboratory
U3 Pharma, an antibody targeted cancer drug development affiliate of Daiichi Sankyo, has signed a research collaboration deal with AbCheck. AbCheck's commercial multi antibody discovery platforms include AbSieve, which combines the ...
Pharmaceutical and biotech companies are outsourcing research in order to develop innovative products that meet the rising demand for therapeutics across a range of diseases. The willingness of contract research organisations (CROs) to ...
Tags: Pharmaceutical, CROs, innovative products
Albany Molecular Research (AMRI) and Chai Therapeutics, an affiliate of Bessor Pharma, have signed a licensing deal to develop tubulin inhibitor compound, ALB 109564(a), for cancer treatment. AMRI's ALB 109564(a) is a novel analog ...
Sanford-Burnham Medical Research Institute and Florida Hospital have revamped obesity research partnership with Takeda Pharmaceutical Company for the discovery of novel anti-obesity therapeutics. The extended collaboration leverages new ...
Tags: Sanford-Burnham, Florida Hospital, obesity research, Takeda
Pergamum and Cadila Pharmaceuticals have entered into a strategic collaboration for the development of a new therapeutic peptide targeting infections using a distinctive mechanism. The collaboration will focus on preclinical and clinical ...
Tags: Pergamum, Cadila Pharmaceuticals, strategic collaboration
US-based biopharmaceutical company Hyperion Therapeutics has announced that it has gained approval from US Food and Drug Administration (FDA) for its RAVICTI (glycerol phenylbutyrate) liquid drug. RAVICTI used for treating Urea Cycle ...
Tags: FDA, drug, biopharmaceutical company
Six translational health research centers across the globe have formed an alliance to advance the global international academic and/or not-for-profit drug development. The alliance will also focus on commercializing network, thereby ...